
Astrazeneca (AZN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wal...

AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript
AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript

AstraZeneca Revenue Hurt as Demand for COVID-19 Treatments Slumps; Stock Drops
AstraZeneca PLC's (AZN) American depositary receipts (ADRs) fell more than 4% Thursday after the drug maker reported its profit was hurt by falling demand for COVID-19 treatments.

Jobless Claims Steady; Mixed Q4 for AZN, HSY and PM
We're once again reassured that employment, on a finer week-over-week scale, is not falling off a cliff.

AstraZeneca Slips as Earnings, Cancer Drug Sales Disappoint
Deutsche Bank also cut its rating of the stock to Sell from Buy.

AstraZeneca Earnings Hit By Higher Costs
AstraZeneca reported core earnings for the fourth quarter just short of consensus, but said it expected double-digit percentage growth in 2024.

AstraZeneca sees £2.8bn knocked off its value amid cost concerns
AstraZeneca PLC (LSE:AZN) shares fell 1.8%, wiping £2.8 billion from the value of the business, as lingering concerns on the drug maker's cost base overshadowed better than expected results and str...

AstraZeneca to invest $300 million in US facility for cell therapies
AstraZeneca said on Tuesday it will invest $300 million in a facility in Rockville, Maryland for discovery and development of cell therapies.

NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?
Artificial intelligence grabbed most of the headlines last year, but weight loss stocks were equally noteworthy. It grew slowly for several years but really went stratospheric last year.

AstraZeneca facing three big investor debates as results loom, says Barclays
AstraZeneca PLC (LSE:AZN) shares have continued their underperformance from the final quarter of last year into January, with Barclays identifying three major debates around the stock ahead of this...

Astrazeneca (AZN) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key m...

AstraZeneca (AZN) to Report Q4 Earnings: Here's What to Expect
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

AstraZeneca's Q4 Earnings: Recognizing The Underrated Gem's Growth
AstraZeneca is one of the fastest-growing pharmaceutical companies. On February 8, 2024, the company will publish financial results for the 4th quarter of 2023. From a broader perspective, AstraZen...

AstraZeneca's mini acquisition spree comes as core oncology drugs face pressure
AstraZeneca PLC (LSE:AZN) recently committed to reporting how its business impacts nature as part of annual corporate results, but next Thursday's final results are not likely to focus on anything ...

3 No-Brainer Stocks to Buy With $500 Right Now
Wall Street's major stock indexes have oscillated between bear and bull markets in successive years since this decade began. Despite a strong performance from Wall Street in 2023, bargains can stil...
Related Companies